Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Erin Doser

Nurse Practitioner, Adult Health Saint Louis, MO Nurse Practitioner

NPI 1588019715 CMS profile 10696602

12855 N 40 Dr Ste 375, Saint Louis, MO 63141

Open in the dashboard

General payments

$12,543

328 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Erin Doser of Saint Louis, MO is reported in the CMS Open Payments database as having received $12,543 across 328 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Nurse Practitioner, Adult Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $6,049 123
2024 General $3,715 114
2023 General $2,644 83
2021 General $137 8

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Erin Doser
  • Nurse Practitioner, Adult Health median
  • Middle half of Nurse Practitioner, Adult Health
  • National median

In program year 2025, general payments to Erin Doser were reported at $6,049. Among 12,696 Nurse Practitioner, Adult Health profiles paid that year, the median was $184 and the middle half received between $59 and $580.

Show as a table
Year Erin Doser Nurse Practitioner, Adult Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $137 $138 $43–$438 $132
2022 $0 $165 $54–$494 $149
2023 $2,644 $178 $61–$549 $160
2024 $3,715 $186 $62–$575 $164
2025 $6,049 $184 $59–$580 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Janssen Biotech, Inc. $4,516 81 payments
  2. Sumitomo Pharma America, Inc. $927 54 payments
  3. Janssen Scientific Affairs, LLC $749 2 payments
  4. Myriad Genetic Laboratories, Inc. $588 14 payments
  5. Dendreon Pharmaceuticals LLC $557 23 payments
  6. Bayer HealthCare Pharmaceuticals Inc. $525 12 payments
  7. Medtronic, Inc. $442 3 payments
  8. PROCEPT BioRobotics Corporation $411 8 payments
  9. Ferring Pharmaceuticals Inc. $363 8 payments
  10. Merck Sharp & Dohme Corporation $346 15 payments
  11. Other $3,120 108 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $10,063 325 payments
  2. Consulting Fee $2,380 2 payments
  3. Education $100 1 payment
Products named General payments · program years 2021–2025
  1. ERLEADA $4,045 76 payments
  2. AKEEGA $2,262 24 payments
  3. PROLARIS $588 14 payments
  4. PROVENGE $557 23 payments
  5. GEMTESA $500 36 payments
  6. INTERSTIM $442 3 payments
  7. Nubeqa $392 11 payments
  8. ADSTILADRIN $339 7 payments
  9. RYBREVANT $326 3 payments
  10. CARVYKTI $326 3 payments
  11. Other $5,407 195 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

902

Median for Nurse Practitioner: 389

Drug cost

$62,846

Median for Nurse Practitioner: $21,885

Branded share of claims

27.7%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gemtesa Vibegron Brand 49 $31,435
Myrbetriq Mirabegron Brand 32 $23,837
Tamsulosin Hcl Generic 324 $2,914
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 63 $894
Solifenacin Succinate Generic 19 $867
Finasteride Generic 112 $789
Oxybutynin Chloride Er Oxybutynin Chloride Brand 13 $566
Ciprofloxacin Hcl Generic 90 $357
Dutasteride Generic 12 $297
Doxycycline Monohydrate Generic 31 $294

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 44 billing codes

Paid by Medicare

$299,379

Of which drugs: $220,914

Medicare patients

581

Average age 76

Services billed

28,470

119 women, 462 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 49%
Cancer 48%
Ischemic heart disease 33%
Diabetes 30%
Chronic kidney disease 25%
Atrial fibrillation 22%
Heart failure 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Leuprolide injectable, camcevi, 1 mg J1952 Office 49 2,646 $119,653
Leuprolide acetate (for depot suspension), 7.5 mg J9217 Office 40 252 $34,724
Injection, degarelix, 1 mg J9155 Office 45 10,680 $34,667
Bcg live intravesical instillation, 1 mg J9030 Office 64 8,416 $18,885
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 22 2,193 $223

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ERLEADA
  • Janssen Biotech, Inc. $873
$873 — —
AKEEGA
  • Janssen Biotech, Inc. $224
$224 — —
ORGOVYX
  • Sumitomo Pharma America, Inc. $190
  • PFIZER INC. $23
$213 — —
GEMTESA
  • Sumitomo Pharma America, Inc. $206
$206 49 —
ADSTILADRIN
  • Ferring Pharmaceuticals Inc. $170
$170 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

328 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Adult Health in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record